William Chung
Family · Brooklyn, NYNPI 1043809031
Payments from drug & device makers
Across 281 payments — averaging $24.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$2K
- Amgen$867
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$601
- Esperion Therapeutics, Inc.$514
- IBSA Pharma Inc.$476
- Phathom Pharmaceuticals, Inc.$345
- plus $2K from 16 others
What the payments were for
- Food & beverage$6,985100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 39 | $1,720 |
| Amgen | 23 | $867 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 38 | $601 |
| Esperion Therapeutics, Inc. | 32 | $514 |
| IBSA Pharma Inc. | 19 | $476 |
| Phathom Pharmaceuticals, Inc. | 12 | $345 |
| Ardelyx, Inc. | 17 | $344 |
| Exact Sciences | 14 | $334 |
| Pfizer | 12 | $281 |
| Boehringer Ingelheim | 13 | $279 |
| Lilly USA, LLC | 12 | $226 |
| Merck | 9 | $181 |
| Novo Nordisk | 10 | $152 |
| AbbVie | 7 | $150 |
| Bayer | 5 | $133 |
| GSK | 6 | $116 |
| Amarin Pharma, Inc. | 5 | $99 |
| Kestra Medical Technology Services, Inc. | 1 | $50 |
| Shield Therapeutics Inc | 3 | $48 |
| AstraZeneca | 2 | $36 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,985 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VascepaIcosapent Ethyl | 398 | $143,034 |
| VemlidyTenofovir Alafenamide | 66 | $91,216 |
| JardianceEmpagliflozin | 97 | $64,235 |
| Diclofenac Epolamine | 91 | $59,422 |
| ProliaDenosumab | 25 | $42,322 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 29 | $34,519 |
| Diclofenac Sodium | 83 | $29,663 |
| JanuviaSitagliptin Phosphate | 40 | $27,420 |
| RybelsusSemaglutide | 25 | $26,005 |
| JanumetSitagliptin Phos/Metformin Hcl | 42 | $25,703 |
| EliquisApixaban | 42 | $25,051 |
| FarxigaDapagliflozin Propanediol | 33 | $19,898 |
| TrulicityDulaglutide | 16 | $15,319 |
| LinzessLinaclotide | 29 | $14,408 |
| VireadTenofovir Disoproxil Fumarate | 11 | $11,959 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadVemlidy, Viread | $1,720 | $103,17577 claims |
| Boehringer IngelheimJardiance, Tradjenta, Jentadueto | $279 | $78,426126 claims |
| MerckJanuvia, Janumet | $181 | $53,12382 claims |
| AmgenProlia | $867 | $42,32225 claims |
| Novo NordiskRybelsus | $152 | $26,00525 claims |
| AbbVieLinzess, Restasis | $150 | $25,96345 claims |
| PfizerEliquis | $281 | $25,05142 claims |
| AstraZenecaFarxiga | $36 | $19,89833 claims |
| Lilly USA, LLCTrulicity | $226 | $15,31916 claims |
| IBSA Pharma Inc.Licart | $476 | $11,63216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.
Other family in Brooklyn
- Seida VelijaBrooklyn$62K
- Ofiong OkonBrooklyn$44K
- Irina FainbergBrooklyn$23K
- Susan WeissBrooklyn$22K
- Razan AlawadhiBrooklyn$21K
- Christina LaoBrooklyn$20K
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.